Literature DB >> 7934716

Willingness to pay: a valid and reliable measure of health state preference?

B O'Brien1, J L Viramontes.   

Abstract

The development of methods to measure willingness to pay (WTP) has renewed interest in cost-benefit analysis (CBA) for the economic evaluation of health care programs. The authors studied the construct validity and test-retest reliability of WTP as a measure of health state preferences in a survey of 102 persons (mean age 62 years; 54% male) who had chronic lung disease (forced expiratory volume < 70%). Interview measurements included self-reported symptoms, the oxygen-cost diagram for dyspnea, Short-Form 36 for general health status, rating scale and standard gamble for value and utility of current health state relative to death and healthy lung functioning, and WTP for a hypothetical intervention offering a 99% chance of healthy lung functioning and a 1% chance of death. WTP was elicited by a simple bidding game. To test for starting-point bias, the respondents were randomly assigned to one of five starting bids. All health status and preference measurements except WTP (controlling for income) showed significant (p < 0.05) difference between disease-severity groups (mild/moderate/severe). WTP was significantly (p = 0.01) associated with household income, but other health status and preference measure were not. The measure most highly correlated with WTP was standard gamble (r = -0.46). There was no association between starting bid and mean WTP adjusted for income and health status. The test-retest reliability of WTP was acceptable (r = 0.66) but lower than that for the standard gamble (r = 0.82).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 7934716     DOI: 10.1177/0272989X9401400311

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  42 in total

1.  Public involvement in health care priority setting: an overview of methods for eliciting values.

Authors:  Penelope M. Mullen
Journal:  Health Expect       Date:  1999-12       Impact factor: 3.377

Review 2.  Valuing health-related quality of life. A review of health state valuation techniques.

Authors:  C Green; J Brazier; M Deverill
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

3.  Willingness to pay for mammography: item development and testing among five ethnic groups.

Authors:  T H Wagner; T W Hu; G V Dueñas; R J Pasick
Journal:  Health Policy       Date:  2000-09       Impact factor: 2.980

Review 4.  A review of alternative approaches to healthcare resource allocation.

Authors:  S Petrou; J Wolstenholme
Journal:  Pharmacoeconomics       Date:  2000-07       Impact factor: 4.981

Review 5.  Willingness to pay as a measure of health benefits.

Authors:  M V Bala; J A Mauskopf; L L Wood
Journal:  Pharmacoeconomics       Date:  1999-01       Impact factor: 4.981

6.  Prostate cancer: 12. The economic burden.

Authors:  S A Grover; H Zowall; L Coupal; M D Krahn
Journal:  CMAJ       Date:  1999-03-09       Impact factor: 8.262

Review 7.  Quality-of-life measures as providers of information on value-for-money of health interventions. Comparison and recommendations for practice.

Authors:  M E Hyland
Journal:  Pharmacoeconomics       Date:  1997-01       Impact factor: 4.981

8.  Willingness to pay as patient preference to bariatric surgery.

Authors:  Cristina Khawali; Marcos B Ferraz; Maria T Zanella; Sandra R G Ferreira
Journal:  Health Expect       Date:  2011-11-10       Impact factor: 3.377

9.  The stability of utility scores: test-retest reliability and the interpretation of utility scores in elective total hip arthroplasty.

Authors:  D Feeny; C M Blanchard; J L Mahon; R Bourne; C Rorabeck; L Stitt; S Webster-Bogaert
Journal:  Qual Life Res       Date:  2004-02       Impact factor: 4.147

Review 10.  Statistical versus quantitative significance in the socioeconomic evaluation of medicines.

Authors:  B J O'Brien; M F Drummond
Journal:  Pharmacoeconomics       Date:  1994-05       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.